Waigamicin A Gel is a topical dermatological formulation containing Adapalene 0.1% w/w and Clindamycin 1% w/w, indicated for the treatment of acne vulgaris. Adapalene, a third-generation synthetic retinoid, exerts comedolytic, anti-inflammatory, and keratolytic effects by modulating cellular differentiation and proliferation within the follicular epithelium, thereby preventing the formation of microcomedones. Clindamycin, a lincosamide antibiotic, inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, effectively reducing Cutibacterium acnes colonization and associated inflammatory lesions. The combination of these agents targets multiple pathogenic factors of acne, including follicular hyperkeratinization, bacterial proliferation, and inflammation. Waigamicin A Gel is applied once daily to the affected areas, preferably in the evening, after cleansing the skin. Common adverse effects may include mild erythema, dryness, peeling, and irritation at the application site, which typically diminish with continued use. Patients are advised to avoid excessive sun exposure and use sunscreen during treatment. Waigamicin A Gel should be used under medical supervision, particularly in individuals with known hypersensitivity to retinoids or clindamycin. This combination therapy offers an effective and well-tolerated option for managing inflammatory and non-inflammatory acne lesions.